Health Care Consultants Publish Research on the Economic Benefits of Diabetic Foot Ulcer Treatment

March 27, 2015

Treating patients with diabetic foot ulcers (DFU) with bioengineered living cellular technologies may reduce health care services and overall medical costs, according to a recent study conducted by a team of researchers from Analysis Group in collaboration with Organogenesis. The study, "Economic Outcomes among Medicare Patients Receiving Bioengineered Cellular Technologies for Treatment of Diabetic Foot Ulcers" (Journal of Medical Economics, March 19, 2015), assessed the real-world Medicare costs associated with the use of DFU treatments Apligraf and Dermagraft compared to conventional DFU care. The researchers, including  Principal Howard Birnbaum, Vice President Brad Rice, and Associate Urvi Desai, analyzed administrative claims data of more than 20,000 Medicare patients from 2006 to 2012 and found that patients using these treatments experienced lower amputation rates and fewer hospitalizations and emergency room visits, resulting in lower per-patient health care costs.

"The objective of this study was to expand and improve on previous research to compare the real-world medical services utilization, rates of lower-limb amputations, and costs for Medicare DFU patients treated with bioengineered cellular technologies," said Dr. Rice in a related Organogenesis press release. "Propensity score matching technique was used to account for differences across treatment groups. In the field of wound care technologies, this type of robust analysis has never before been conducted."

Read the study abstract

Read the press release